ALTAMIRA THERAPEUTICS LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.6 USD | +11.11% |
|
+13.15% | -54.02% |
Valuation
| Fiscal Period: December | 2019 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 5.174 | 3.463 | - | - |
| Enterprise Value (EV) 1 | 3.789 | 3.463 | 3.463 | 3.463 |
| P/E ratio | -0.71 x | - | - | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -715,778 x | - | - | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 8.26 | 2,240 | - | - |
| Reference price 2 | 648.0 | 1.690 | 1.690 | 1.690 |
| Announcement Date | 4/16/20 | - | - | - |
1USD in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | -7.228 | - | - | - |
| EBIT 1 | -7.259 | -7,846,208 | -10,287,422 | -12,755,616 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) | -6.826 | - | - | - |
| Net income | -6.632 | - | - | - |
| Net margin | - | - | - | - |
| EPS | -912.0 | - | - | - |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 4/16/20 | - | - | - |
1CHF in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT | -3.152 | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | -3.028 | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | -248.0 | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/16/20 | - | - | - | - |
1CHF in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | 1.38 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | 3.02 | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 4/16/20 | - | - | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -54.02% | 3.79M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CYTO Stock
- Financials Altamira Therapeutics Ltd.
